Thymosin Alpha-1 Sleep Impact and Optimization

HealthRX.com

Thymosin alpha-1 has no established sleep effect

1.8 to 2.6 hoursHalf-life of thymosin alpha-1 after subcutaneous injectionSource: pubmed.ncbi.nlm.nih.gov

Print or save as PDF

Key numbers

  • 0.7 to 2 hoursTime to peak level after subcutaneous injectionSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
  • 1.6 mgItalian label dose: subcutaneous or intramuscular, twice weekly for four weeksSource: fda.gov, as cited Nov 8, 2026
  • 1.8 to 2.6 hoursHalf-life of thymosin alpha-1 after subcutaneous injectionSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
  • Drug / thymosin alpha-1 (thymalfasin), a 28-amino-acid peptide [1]
  • US status / not FDA-approved [1]; FDA proposed not adding it to the pharmacy bulks list [3]
  • Mechanism / immune modulator that augments T-cell function [2]
  • Pharmacokinetics / peak about 0.7 to 2 hours; half-life about 1.8 to 2.6 hours [2][1]
  • Italian label cautions / pregnancy, breastfeeding, children, allergies or autoimmune disease, other immune-modulating drugs [1]
  • Adverse events / FDA database search found zero reports; company-linked data describe infrequent and mild events [1]

Does thymosin alpha-1 affect sleep?

None of the studies cited on this page reported sleep quality, sleep duration, insomnia, or polysomnography results in people taking thymosin alpha-1. Claims about slow-wave sleep, REM sleep, or sleep-onset latency are extrapolations from immune biology, not measured results.

Research on sleep and immunity shows that immune activation can change sleep, and that cytokines such as IL-1 and TNF-alpha alter sleep profiles in experimental work [4][5]. Those findings do not show that thymosin alpha-1 changes sleep duration, sleep stages, or insomnia symptoms.

Questions worth asking

Choose the questions you want to keep

What is known about the drug?

Thymosin alpha-1 is a 28-amino-acid peptide; synthetic thymalfasin is sold outside the US as Zadaxin 1.6 mg per vial [1]. It is an immune modulator that augments T-cell function [2]. After subcutaneous injection, peak levels occur at about 0.7 to 2 hours, the half-life is about 1.8 to 2.6 hours, and daily dosing for five days produced no accumulation [2][1].

It is not FDA-approved; its four US orphan drug designations are not an approval [1]. FDA lists approval in Italy as an influenza-vaccine adjuvant in immunocompromised people, in India for chronic hepatitis B, and in Hong Kong [1]. In December 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on adding it to the pharmacy bulks list [3]. The Italian label gives 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 at the second [1]. That is a vaccine-adjuvant regimen, not a sleep protocol.

What does the label warn about?

The Italian Zadaxin label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

What is known about adverse events?

FDA's adverse-event database search on April 22, 2024 found zero reports [1]. Authors tied to the manufacturer report more than 4,400 trial participants and more than 17 million marketed doses, with adverse experiences described as infrequent and mild; that is company-linked data [1]. A 2026 Cochrane review of hepatitis B trials found that thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low certainty) and fewer non-serious events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low certainty) [6].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, do the studies cited on this page report sleep outcomes for people taking thymosin alpha-1?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Is thymosin alpha-1 FDA-approved in the US?
No. FDA's December 2024 review found no US application for thymosin alpha-1. It has four orphan drug designations, but orphan designation is not approval [1].
What dose does the Italian label use?
Zadaxin 1.6 mg is given subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. No US-approved dose exists [1].
What adverse events are reported?
FDA's adverse-event database search found zero reports. Company-linked data covering more than 4,400 trial participants and more than 17 million marketed doses describe adverse experiences as infrequent and mild [1]. A 2026 Cochrane review of hepatitis B trials found that it may have caused fewer serious and non-serious events than comparison treatments, with low to very low certainty [6].
Does the label warn about other immune drugs?
The Italian Zadaxin label calls for caution with other immune-modulating drugs. It also lists caution in people with allergies or autoimmune disease and contraindicates use in pregnancy and breastfeeding [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Does taking peptides affect sleep?

For thymosin alpha-1, the effect on sleep is not established. None of the cited studies measured sleep quality, sleep duration, insomnia, or polysomnography results in people taking it. Immune signals such as IL-1 and TNF-alpha can alter sleep in experimental work, but that does not show thymosin alpha-1 does the same.

How much thymosin alpha should I take?

No US-approved dose exists. The Italian label gives 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That is a vaccine-adjuvant regimen, not a sleep protocol.

Is thymosin alpha 1 anti-inflammatory?

An anti-inflammatory effect is not established for thymosin alpha-1. It is described as an immune modulator that augments T-cell function. After subcutaneous injection, peak levels occur at about 0.7 to 2 hours, and the half-life is about 1.8 to 2.6 hours.

How long should you be on thymosin alpha 1?

No duration for sleep or general use is established. Because the drug is not FDA-approved in the US, no US duration guidance exists. The only regimen given is the Italian label's: 1.6 mg twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12.

Show all 6 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  3. U.S. Food and Drug Administration.
  4. Besedovsky L, Lange T, Haack M. The Sleep-Immune Crosstalk in Health and Disease. Physiol Rev. 2019;99(3):1325-1380.
  5. Krueger JM, Majde JA. Humoral links between sleep and the immune system: research issues. Ann N Y Acad Sci. 2003;992:9-20.
  6. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
Evidence overview for Thymosin Alpha-1 Sleep Impact and Optimization